Tonix Pharmaceuticals Holding Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting accelerating operating losses alongside significant growth in product revenue.

Key Highlights

  • Net loss for the nine months ended September 30, 2026: $134,075 thousand, compared to $77,111 thousand for the same period in 2025, according to the filing.
  • Product revenue, net for the nine months ended September 30, 2026: $37,656 thousand, up from $7,717 thousand in the comparable prior-year period.
  • Cash and cash equivalents as of September 30, 2026: $162,793 thousand, down from $207,637 thousand at December 31, 2025.
  • Total stockholders' equity as of September 30, 2026: $199,485 thousand, compared to $245,150 thousand at December 31, 2025.
  • Common shares outstanding as of November 6, 2026: 19,431,516 shares.
  • ATM program issuances during the nine months: proceeds raised across three tranches totaling approximately $81,714 thousand net of transactional expenses.
  • Accumulated deficit as of September 30, 2026: $988,790 thousand.

Tonix Pharmaceuticals Financial Results for the Quarter and Nine Months Ended September 30, 2026

According to the filing, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) reported a net loss of $53,329 thousand for the three months ended September 30, 2026, compared to a net loss of $32,010 thousand in the same quarter of 2025. For the nine-month period, the net loss was $134,075 thousand versus $77,111 thousand a year earlier. Net loss per common share, basic and diluted, was $(2.89) for the third quarter of 2026 and $(8.24) for the nine months ended September 30, 2026, based on weighted average shares of 18,440,773 and 16,278,383, respectively, the company disclosed.

The filing reported that product revenue, net reached $17,234 thousand in the third quarter of 2026, compared to $3,290 thousand in the third quarter of 2025, and $37,656 thousand for the nine months ended September 30, 2026, versus $7,717 thousand in the comparable prior-year period. Total operating expenses for the nine months were $177,160 thousand, driven primarily by selling, general and administrative expenses of $110,173 thousand and research and development expenses of $63,454 thousand, according to the filing. Operating loss for the nine-month period was reported as $139,504 thousand.

On the balance sheet, total assets were $242,426 thousand as of September 30, 2026, down from $277,171 thousand at December 31, 2025, the registrant reported. Total liabilities increased to $42,941 thousand from $32,021 thousand over the same period. The company raised additional capital through its at-the-market program during the nine months, issuing shares in three separate tranches net of transactional expenses of $676 thousand, $1,049 thousand, and $896 thousand, respectively, as disclosed in the stockholders' equity statement. The accumulated deficit stood at $988,790 thousand as of September 30, 2026.

What Was Disclosed

Tonix Pharmaceuticals filed its quarterly report for the period ended September 30, 2026, disclosing a nine-month net loss of $134,075 thousand, product revenue of $37,656 thousand, cash of $162,793 thousand, and 19,431,516 shares outstanding as of November 6, 2026.